1. Home
  2. Directory
  3. New Jersey
  4. Somerville
  5. Urology
  6. NPI Profile
  7. Prescriptions 1619997749

MR. JOEL M FISCHER MD
Prescription History 1619997749
Urology in Somerville, NJ


Quality Rating: 93.71 out of 100 score

NPI Status: Active since July 20, 2006

Contact Information

72 W END AVE
SOMERVILLE, NJ
ZIP 08876
Phone: (908) 927-0300
Fax: (908) 707-4988

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. JOEL M FISCHER MD, an active Urology specialist practicing in Somerville, NJ. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 244 documented patient claims. Among these therapy options, the most frequently utilized medication is Finasteride, which accounts for 85 claims alone.

Medication Index

Allopurinol

Generic Formulation: AllopurinolSpecialty: Urology
Provider Metrics Summary
Total Claims 19
30-Day Fills 57.0
Days Supply 1,710
NJ State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills99.8
Peer Average Days Supply2,968
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $243.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.82

State Avg Cost Per Claim

$17.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Dutasteride

Generic Formulation: DutasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 13
30-Day Fills 39.7
Days Supply 1,190
NJ State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills96.9
Peer Average Days Supply2,897
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.8% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $548.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.18

State Avg Cost Per Claim

$59.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

Therapeutic Applications

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). It may also reduce the need for surgery to treat BPH. Dutasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. This medication should not be used by women or children.

Finasteride

Generic Formulation: FinasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 85
30-Day Fills 245.1
Days Supply 7,350
NJ State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills148.2
Peer Average Days Supply4,404
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 39.3% more claims than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,330.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.66

State Avg Cost Per Claim

$18.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Urology
Provider Metrics Summary
Total Claims 27
30-Day Fills 71.0
Days Supply 2,105
NJ State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills88.7
Peer Average Days Supply2,570
Conservative Utilization

This provider writes prescriptions for this formulation 49.1% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,596.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,133.20

State Avg Cost Per Claim

$707.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Urology
Provider Metrics Summary
Total Claims 23
30-Day Fills 55.1
Days Supply 1,652
NJ State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills68.3
Peer Average Days Supply2,010
Conservative Utilization

This provider writes prescriptions for this formulation 36.1% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,062.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$89.69

State Avg Cost Per Claim

$46.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 77
30-Day Fills 217.0
Days Supply 6,510
NJ State Average Benchmarks
Peer Average Claims86.0
Peer Average 30-Day Fills192.2
Peer Average Days Supply5,691
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,504.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.54

State Avg Cost Per Claim

$21.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. JOEL M FISCHER MD provides transparency into local medical care patterns within Somerville, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.